Phase II trial of hypomethylating agent combined with nivolumab for acute myeloid leukaemia relapse after allogeneic haematopoietic cell transplantation—Immune signature correlates...

Autores: Apostolova, Petya; Kreutmair, Stefanie; Toffalori, Cristina; Punta, Marco; Unger, Susanne; Burk, Ann Cathrin; Wehr, Claudia; Maas Bauer, Kristina; Melchinger, Wolfgang; Haring, Eileen; Höfflin, Rouven; Shoumariyeh, Khalid; Hupfer, Valerie; Lauer, Eliza Maria; Duquesne, Sandra; Lowinus, Theresa; Núñez, Nicolás; Alberti, Chiara; da Costa Pereira, Sara; Merten, Carla Helena; Power, Laura; Weiss, Matthias; Böke, Caroline; Pfeifer, Dietmar; Marks, Reinhard; Bertz, Hartmut; Wäsch, Ralph; Ihorst, Gabriele; Gentner, Bernhard; Duyster, Justus; Boerries, Melanie; Andrieux, Geoffroy; Finke, Juergen; Becher, Burkhard; Vago, Luca; Zeiser, Robert
Año de publicación: 2023
Idioma: inglés
Tipo de recurso: artículo
Estado: versión publicada
Descripción: Acute myeloid leukaemia (AML) relapse after allogeneic haematopoietic cell transplantation (allo-HCT) is often driven by immune-related mechanisms and associated with poor prognosis. Immune checkpoint inhibitors combined with hypomethylating agents (HMA) may restore or enhance the graft-versus-leukaemia effect. Still, data about using this combination regimen after allo-HCT are limited. We conducted a prospective, phase II, open-label, single-arm study in which we treated patients with haematological AML relapse after allo-HCT with HMA plus the anti-PD-1 antibody nivolumab. The response was correlated with DNA-, RNA- and protein-based single-cell technology assessments to identify biomarkers associated with therapeutic efficacy. Sixteen patients received a median number of 2 (range 1–7) nivolumab applications. The overall response rate (CR/PR) at day 42 was 25%, and another 25% of the patients achieved stable disease. The median overall survival was 15.6 months. High-parametric cytometry documented a higher frequency of activated (ICOS+, HLA-DR+), low senescence (KLRG1−, CD57−) CD8+ effector T cells in responders. We confirmed these findings in a preclinical model. Single-cell transcriptomics revealed a pro-inflammatory rewiring of the expression profile of T and myeloid cells in responders. In summary, the study indicates that the post-allo-HCT HMA/nivolumab combination induces anti-AML immune responses in selected patients and could be considered as a bridging approach to a second allo-HCT.
Fil: Apostolova, Petya. Albert Ludwigs University of Freiburg; Alemania. German Cancer Research Center; Alemania
Fil: Kreutmair, Stefanie. Universitat Zurich; Suiza. German Cancer Research Center; Alemania
Fil: Toffalori, Cristina. Istituto di Ricovero e Cura a Carattere Scientifico; Italia
Fil: Punta, Marco. Istituto di Ricovero e Cura a Carattere Scientifico; Italia
Fil: Unger, Susanne. Universitat Zurich; Suiza
Fil: Burk, Ann Cathrin. Universite de Fribourg (unifr); . German Cancer Research Center; Alemania
Fil: Wehr, Claudia. Universite de Fribourg (unifr);
Fil: Maas Bauer, Kristina. Universite de Fribourg (unifr);
Fil: Melchinger, Wolfgang. Universite de Fribourg (unifr);
Fil: Haring, Eileen. Universite de Fribourg (unifr); . German Cancer Research Center; Alemania
Fil: Höfflin, Rouven. Universite de Fribourg (unifr);
Fil: Shoumariyeh, Khalid. Universite de Fribourg (unifr);
Fil: Hupfer, Valerie. Universite de Fribourg (unifr);
Fil: Lauer, Eliza Maria. Universite de Fribourg (unifr);
Fil: Duquesne, Sandra. Universite de Fribourg (unifr);
Fil: Lowinus, Theresa. Universite de Fribourg (unifr);
Fil: Núñez, Nicolás. Universitat Zurich; Suiza. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Córdoba. Centro de Investigaciones en Bioquímica Clínica e Inmunología; Argentina
Fil: Alberti, Chiara. Universitat Zurich; Suiza
Fil: da Costa Pereira, Sara. Universitat Zurich; Suiza
Fil: Merten, Carla Helena. Universitat Zurich; Suiza
Fil: Power, Laura. Universitat Zurich; Suiza
Fil: Weiss, Matthias. Universite de Fribourg (unifr);
Fil: Böke, Caroline. Universite de Fribourg (unifr);
Fil: Pfeifer, Dietmar. Universite de Fribourg (unifr);
Fil: Marks, Reinhard. Universite de Fribourg (unifr);
Fil: Bertz, Hartmut. Universite de Fribourg (unifr);
Fil: Wäsch, Ralph. Universite de Fribourg (unifr);
Fil: Ihorst, Gabriele. Universite de Fribourg (unifr);
Fil: Gentner, Bernhard. Istituto di Ricovero e Cura a Carattere Scientifico; Italia. Universite de Lausanne; Suiza
Fil: Duyster, Justus. Universite de Fribourg (unifr);
Fil: Boerries, Melanie. German Cancer Research Center; Alemania. Universite de Fribourg (unifr);
Fil: Andrieux, Geoffroy. Universite de Fribourg (unifr);
Fil: Finke, Juergen. Universite de Fribourg (unifr);
Fil: Becher, Burkhard. Universitat Zurich; Suiza
Fil: Vago, Luca. Istituto di Ricovero e Cura a Carattere Scientifico; Italia. Vita Salute Universidad San Raffaele; Italia
Fil: Zeiser, Robert. German Cancer Research Center; Alemania. Universite de Fribourg (unifr);
Materia: AML
HCT
HMA
Nivel de accesibilidad: acceso abierto
Condiciones de uso: https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
Repositorio
Institución: Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador: oai:ri.conicet.gov.ar:11336/241849

Acceder

id	CONICETDig_c5de122a2df79dedf9095dce33cd4779
oai_identifier_str	oai:ri.conicet.gov.ar:11336/241849
network_acronym_str	CONICETDig
repository_id_str	3498
network_name_str	CONICET Digital (CONICET)
spelling	Phase II trial of hypomethylating agent combined with nivolumab for acute myeloid leukaemia relapse after allogeneic haematopoietic cell transplantation—Immune signature correlates with responseApostolova, PetyaKreutmair, StefanieToffalori, CristinaPunta, MarcoUnger, SusanneBurk, Ann CathrinWehr, ClaudiaMaas Bauer, KristinaMelchinger, WolfgangHaring, EileenHöfflin, RouvenShoumariyeh, KhalidHupfer, ValerieLauer, Eliza MariaDuquesne, SandraLowinus, TheresaNúñez, NicolásAlberti, Chiarada Costa Pereira, SaraMerten, Carla HelenaPower, LauraWeiss, MatthiasBöke, CarolinePfeifer, DietmarMarks, ReinhardBertz, HartmutWäsch, RalphIhorst, GabrieleGentner, BernhardDuyster, JustusBoerries, MelanieAndrieux, GeoffroyFinke, JuergenBecher, BurkhardVago, LucaZeiser, RobertAMLHCTHMAhttps://purl.org/becyt/ford/3.1https://purl.org/becyt/ford/3Acute myeloid leukaemia (AML) relapse after allogeneic haematopoietic cell transplantation (allo-HCT) is often driven by immune-related mechanisms and associated with poor prognosis. Immune checkpoint inhibitors combined with hypomethylating agents (HMA) may restore or enhance the graft-versus-leukaemia effect. Still, data about using this combination regimen after allo-HCT are limited. We conducted a prospective, phase II, open-label, single-arm study in which we treated patients with haematological AML relapse after allo-HCT with HMA plus the anti-PD-1 antibody nivolumab. The response was correlated with DNA-, RNA- and protein-based single-cell technology assessments to identify biomarkers associated with therapeutic efficacy. Sixteen patients received a median number of 2 (range 1–7) nivolumab applications. The overall response rate (CR/PR) at day 42 was 25%, and another 25% of the patients achieved stable disease. The median overall survival was 15.6 months. High-parametric cytometry documented a higher frequency of activated (ICOS+, HLA-DR+), low senescence (KLRG1−, CD57−) CD8+ effector T cells in responders. We confirmed these findings in a preclinical model. Single-cell transcriptomics revealed a pro-inflammatory rewiring of the expression profile of T and myeloid cells in responders. In summary, the study indicates that the post-allo-HCT HMA/nivolumab combination induces anti-AML immune responses in selected patients and could be considered as a bridging approach to a second allo-HCT.Fil: Apostolova, Petya. Albert Ludwigs University of Freiburg; Alemania. German Cancer Research Center; AlemaniaFil: Kreutmair, Stefanie. Universitat Zurich; Suiza. German Cancer Research Center; AlemaniaFil: Toffalori, Cristina. Istituto di Ricovero e Cura a Carattere Scientifico; ItaliaFil: Punta, Marco. Istituto di Ricovero e Cura a Carattere Scientifico; ItaliaFil: Unger, Susanne. Universitat Zurich; SuizaFil: Burk, Ann Cathrin. Universite de Fribourg (unifr); . German Cancer Research Center; AlemaniaFil: Wehr, Claudia. Universite de Fribourg (unifr);Fil: Maas Bauer, Kristina. Universite de Fribourg (unifr);Fil: Melchinger, Wolfgang. Universite de Fribourg (unifr);Fil: Haring, Eileen. Universite de Fribourg (unifr); . German Cancer Research Center; AlemaniaFil: Höfflin, Rouven. Universite de Fribourg (unifr);Fil: Shoumariyeh, Khalid. Universite de Fribourg (unifr);Fil: Hupfer, Valerie. Universite de Fribourg (unifr);Fil: Lauer, Eliza Maria. Universite de Fribourg (unifr);Fil: Duquesne, Sandra. Universite de Fribourg (unifr);Fil: Lowinus, Theresa. Universite de Fribourg (unifr);Fil: Núñez, Nicolás. Universitat Zurich; Suiza. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Córdoba. Centro de Investigaciones en Bioquímica Clínica e Inmunología; ArgentinaFil: Alberti, Chiara. Universitat Zurich; SuizaFil: da Costa Pereira, Sara. Universitat Zurich; SuizaFil: Merten, Carla Helena. Universitat Zurich; SuizaFil: Power, Laura. Universitat Zurich; SuizaFil: Weiss, Matthias. Universite de Fribourg (unifr);Fil: Böke, Caroline. Universite de Fribourg (unifr);Fil: Pfeifer, Dietmar. Universite de Fribourg (unifr);Fil: Marks, Reinhard. Universite de Fribourg (unifr);Fil: Bertz, Hartmut. Universite de Fribourg (unifr);Fil: Wäsch, Ralph. Universite de Fribourg (unifr);Fil: Ihorst, Gabriele. Universite de Fribourg (unifr);Fil: Gentner, Bernhard. Istituto di Ricovero e Cura a Carattere Scientifico; Italia. Universite de Lausanne; SuizaFil: Duyster, Justus. Universite de Fribourg (unifr);Fil: Boerries, Melanie. German Cancer Research Center; Alemania. Universite de Fribourg (unifr);Fil: Andrieux, Geoffroy. Universite de Fribourg (unifr);Fil: Finke, Juergen. Universite de Fribourg (unifr);Fil: Becher, Burkhard. Universitat Zurich; SuizaFil: Vago, Luca. Istituto di Ricovero e Cura a Carattere Scientifico; Italia. Vita Salute Universidad San Raffaele; ItaliaFil: Zeiser, Robert. German Cancer Research Center; Alemania. Universite de Fribourg (unifr);Wiley Blackwell Publishing, Inc2023-10info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/241849Apostolova, Petya; Kreutmair, Stefanie; Toffalori, Cristina; Punta, Marco; Unger, Susanne; et al.; Phase II trial of hypomethylating agent combined with nivolumab for acute myeloid leukaemia relapse after allogeneic haematopoietic cell transplantation—Immune signature correlates with response; Wiley Blackwell Publishing, Inc; British Journal of Haematology; 203; 2; 10-2023; 264-2811365-2141CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/doi/10.1111/bjh.19007info:eu-repo/semantics/altIdentifier/url/https://onlinelibrary.wiley.com/doi/10.1111/bjh.19007info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-29T10:00:39Zoai:ri.conicet.gov.ar:11336/241849instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-29 10:00:39.717CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv	Phase II trial of hypomethylating agent combined with nivolumab for acute myeloid leukaemia relapse after allogeneic haematopoietic cell transplantation—Immune signature correlates with response
title	Phase II trial of hypomethylating agent combined with nivolumab for acute myeloid leukaemia relapse after allogeneic haematopoietic cell transplantation—Immune signature correlates with response
spellingShingle	Phase II trial of hypomethylating agent combined with nivolumab for acute myeloid leukaemia relapse after allogeneic haematopoietic cell transplantation—Immune signature correlates with response Apostolova, Petya AML HCT HMA
title_short	Phase II trial of hypomethylating agent combined with nivolumab for acute myeloid leukaemia relapse after allogeneic haematopoietic cell transplantation—Immune signature correlates with response
title_full	Phase II trial of hypomethylating agent combined with nivolumab for acute myeloid leukaemia relapse after allogeneic haematopoietic cell transplantation—Immune signature correlates with response
title_fullStr	Phase II trial of hypomethylating agent combined with nivolumab for acute myeloid leukaemia relapse after allogeneic haematopoietic cell transplantation—Immune signature correlates with response
title_full_unstemmed	Phase II trial of hypomethylating agent combined with nivolumab for acute myeloid leukaemia relapse after allogeneic haematopoietic cell transplantation—Immune signature correlates with response
title_sort	Phase II trial of hypomethylating agent combined with nivolumab for acute myeloid leukaemia relapse after allogeneic haematopoietic cell transplantation—Immune signature correlates with response
dc.creator.none.fl_str_mv	Apostolova, Petya Kreutmair, Stefanie Toffalori, Cristina Punta, Marco Unger, Susanne Burk, Ann Cathrin Wehr, Claudia Maas Bauer, Kristina Melchinger, Wolfgang Haring, Eileen Höfflin, Rouven Shoumariyeh, Khalid Hupfer, Valerie Lauer, Eliza Maria Duquesne, Sandra Lowinus, Theresa Núñez, Nicolás Alberti, Chiara da Costa Pereira, Sara Merten, Carla Helena Power, Laura Weiss, Matthias Böke, Caroline Pfeifer, Dietmar Marks, Reinhard Bertz, Hartmut Wäsch, Ralph Ihorst, Gabriele Gentner, Bernhard Duyster, Justus Boerries, Melanie Andrieux, Geoffroy Finke, Juergen Becher, Burkhard Vago, Luca Zeiser, Robert
author	Apostolova, Petya
author_facet	Apostolova, Petya Kreutmair, Stefanie Toffalori, Cristina Punta, Marco Unger, Susanne Burk, Ann Cathrin Wehr, Claudia Maas Bauer, Kristina Melchinger, Wolfgang Haring, Eileen Höfflin, Rouven Shoumariyeh, Khalid Hupfer, Valerie Lauer, Eliza Maria Duquesne, Sandra Lowinus, Theresa Núñez, Nicolás Alberti, Chiara da Costa Pereira, Sara Merten, Carla Helena Power, Laura Weiss, Matthias Böke, Caroline Pfeifer, Dietmar Marks, Reinhard Bertz, Hartmut Wäsch, Ralph Ihorst, Gabriele Gentner, Bernhard Duyster, Justus Boerries, Melanie Andrieux, Geoffroy Finke, Juergen Becher, Burkhard Vago, Luca Zeiser, Robert
author_role	author
author2	Kreutmair, Stefanie Toffalori, Cristina Punta, Marco Unger, Susanne Burk, Ann Cathrin Wehr, Claudia Maas Bauer, Kristina Melchinger, Wolfgang Haring, Eileen Höfflin, Rouven Shoumariyeh, Khalid Hupfer, Valerie Lauer, Eliza Maria Duquesne, Sandra Lowinus, Theresa Núñez, Nicolás Alberti, Chiara da Costa Pereira, Sara Merten, Carla Helena Power, Laura Weiss, Matthias Böke, Caroline Pfeifer, Dietmar Marks, Reinhard Bertz, Hartmut Wäsch, Ralph Ihorst, Gabriele Gentner, Bernhard Duyster, Justus Boerries, Melanie Andrieux, Geoffroy Finke, Juergen Becher, Burkhard Vago, Luca Zeiser, Robert
author2_role	author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author
dc.subject.none.fl_str_mv	AML HCT HMA
topic	AML HCT HMA
purl_subject.fl_str_mv	https://purl.org/becyt/ford/3.1 https://purl.org/becyt/ford/3
dc.description.none.fl_txt_mv	Acute myeloid leukaemia (AML) relapse after allogeneic haematopoietic cell transplantation (allo-HCT) is often driven by immune-related mechanisms and associated with poor prognosis. Immune checkpoint inhibitors combined with hypomethylating agents (HMA) may restore or enhance the graft-versus-leukaemia effect. Still, data about using this combination regimen after allo-HCT are limited. We conducted a prospective, phase II, open-label, single-arm study in which we treated patients with haematological AML relapse after allo-HCT with HMA plus the anti-PD-1 antibody nivolumab. The response was correlated with DNA-, RNA- and protein-based single-cell technology assessments to identify biomarkers associated with therapeutic efficacy. Sixteen patients received a median number of 2 (range 1–7) nivolumab applications. The overall response rate (CR/PR) at day 42 was 25%, and another 25% of the patients achieved stable disease. The median overall survival was 15.6 months. High-parametric cytometry documented a higher frequency of activated (ICOS+, HLA-DR+), low senescence (KLRG1−, CD57−) CD8+ effector T cells in responders. We confirmed these findings in a preclinical model. Single-cell transcriptomics revealed a pro-inflammatory rewiring of the expression profile of T and myeloid cells in responders. In summary, the study indicates that the post-allo-HCT HMA/nivolumab combination induces anti-AML immune responses in selected patients and could be considered as a bridging approach to a second allo-HCT. Fil: Apostolova, Petya. Albert Ludwigs University of Freiburg; Alemania. German Cancer Research Center; Alemania Fil: Kreutmair, Stefanie. Universitat Zurich; Suiza. German Cancer Research Center; Alemania Fil: Toffalori, Cristina. Istituto di Ricovero e Cura a Carattere Scientifico; Italia Fil: Punta, Marco. Istituto di Ricovero e Cura a Carattere Scientifico; Italia Fil: Unger, Susanne. Universitat Zurich; Suiza Fil: Burk, Ann Cathrin. Universite de Fribourg (unifr); . German Cancer Research Center; Alemania Fil: Wehr, Claudia. Universite de Fribourg (unifr); Fil: Maas Bauer, Kristina. Universite de Fribourg (unifr); Fil: Melchinger, Wolfgang. Universite de Fribourg (unifr); Fil: Haring, Eileen. Universite de Fribourg (unifr); . German Cancer Research Center; Alemania Fil: Höfflin, Rouven. Universite de Fribourg (unifr); Fil: Shoumariyeh, Khalid. Universite de Fribourg (unifr); Fil: Hupfer, Valerie. Universite de Fribourg (unifr); Fil: Lauer, Eliza Maria. Universite de Fribourg (unifr); Fil: Duquesne, Sandra. Universite de Fribourg (unifr); Fil: Lowinus, Theresa. Universite de Fribourg (unifr); Fil: Núñez, Nicolás. Universitat Zurich; Suiza. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Córdoba. Centro de Investigaciones en Bioquímica Clínica e Inmunología; Argentina Fil: Alberti, Chiara. Universitat Zurich; Suiza Fil: da Costa Pereira, Sara. Universitat Zurich; Suiza Fil: Merten, Carla Helena. Universitat Zurich; Suiza Fil: Power, Laura. Universitat Zurich; Suiza Fil: Weiss, Matthias. Universite de Fribourg (unifr); Fil: Böke, Caroline. Universite de Fribourg (unifr); Fil: Pfeifer, Dietmar. Universite de Fribourg (unifr); Fil: Marks, Reinhard. Universite de Fribourg (unifr); Fil: Bertz, Hartmut. Universite de Fribourg (unifr); Fil: Wäsch, Ralph. Universite de Fribourg (unifr); Fil: Ihorst, Gabriele. Universite de Fribourg (unifr); Fil: Gentner, Bernhard. Istituto di Ricovero e Cura a Carattere Scientifico; Italia. Universite de Lausanne; Suiza Fil: Duyster, Justus. Universite de Fribourg (unifr); Fil: Boerries, Melanie. German Cancer Research Center; Alemania. Universite de Fribourg (unifr); Fil: Andrieux, Geoffroy. Universite de Fribourg (unifr); Fil: Finke, Juergen. Universite de Fribourg (unifr); Fil: Becher, Burkhard. Universitat Zurich; Suiza Fil: Vago, Luca. Istituto di Ricovero e Cura a Carattere Scientifico; Italia. Vita Salute Universidad San Raffaele; Italia Fil: Zeiser, Robert. German Cancer Research Center; Alemania. Universite de Fribourg (unifr);
description	Acute myeloid leukaemia (AML) relapse after allogeneic haematopoietic cell transplantation (allo-HCT) is often driven by immune-related mechanisms and associated with poor prognosis. Immune checkpoint inhibitors combined with hypomethylating agents (HMA) may restore or enhance the graft-versus-leukaemia effect. Still, data about using this combination regimen after allo-HCT are limited. We conducted a prospective, phase II, open-label, single-arm study in which we treated patients with haematological AML relapse after allo-HCT with HMA plus the anti-PD-1 antibody nivolumab. The response was correlated with DNA-, RNA- and protein-based single-cell technology assessments to identify biomarkers associated with therapeutic efficacy. Sixteen patients received a median number of 2 (range 1–7) nivolumab applications. The overall response rate (CR/PR) at day 42 was 25%, and another 25% of the patients achieved stable disease. The median overall survival was 15.6 months. High-parametric cytometry documented a higher frequency of activated (ICOS+, HLA-DR+), low senescence (KLRG1−, CD57−) CD8+ effector T cells in responders. We confirmed these findings in a preclinical model. Single-cell transcriptomics revealed a pro-inflammatory rewiring of the expression profile of T and myeloid cells in responders. In summary, the study indicates that the post-allo-HCT HMA/nivolumab combination induces anti-AML immune responses in selected patients and could be considered as a bridging approach to a second allo-HCT.
publishDate	2023
dc.date.none.fl_str_mv	2023-10
dc.type.none.fl_str_mv	info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion http://purl.org/coar/resource_type/c_6501 info:ar-repo/semantics/articulo
format	article
status_str	publishedVersion
dc.identifier.none.fl_str_mv	http://hdl.handle.net/11336/241849 Apostolova, Petya; Kreutmair, Stefanie; Toffalori, Cristina; Punta, Marco; Unger, Susanne; et al.; Phase II trial of hypomethylating agent combined with nivolumab for acute myeloid leukaemia relapse after allogeneic haematopoietic cell transplantation—Immune signature correlates with response; Wiley Blackwell Publishing, Inc; British Journal of Haematology; 203; 2; 10-2023; 264-281 1365-2141 CONICET Digital CONICET
url	http://hdl.handle.net/11336/241849
identifier_str_mv	Apostolova, Petya; Kreutmair, Stefanie; Toffalori, Cristina; Punta, Marco; Unger, Susanne; et al.; Phase II trial of hypomethylating agent combined with nivolumab for acute myeloid leukaemia relapse after allogeneic haematopoietic cell transplantation—Immune signature correlates with response; Wiley Blackwell Publishing, Inc; British Journal of Haematology; 203; 2; 10-2023; 264-281 1365-2141 CONICET Digital CONICET
dc.language.none.fl_str_mv	eng
language	eng
dc.relation.none.fl_str_mv	info:eu-repo/semantics/altIdentifier/doi/10.1111/bjh.19007 info:eu-repo/semantics/altIdentifier/url/https://onlinelibrary.wiley.com/doi/10.1111/bjh.19007
dc.rights.none.fl_str_mv	info:eu-repo/semantics/openAccess https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
eu_rights_str_mv	openAccess
rights_invalid_str_mv	https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.format.none.fl_str_mv	application/pdf application/pdf
dc.publisher.none.fl_str_mv	Wiley Blackwell Publishing, Inc
publisher.none.fl_str_mv	Wiley Blackwell Publishing, Inc
dc.source.none.fl_str_mv	reponame:CONICET Digital (CONICET) instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str	CONICET Digital (CONICET)
collection	CONICET Digital (CONICET)
instname_str	Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv	CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv	dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_	1844613790186864640
score	13.070432

Phase II trial of hypomethylating agent combined with nivolumab for acute myeloid leukaemia relapse after allogeneic haematopoietic cell transplantation—Immune signature correlates...

Publicaciones similares